<DOC>
	<DOCNO>NCT00985374</DOCNO>
	<brief_summary>This 2 part study ass safety , tolerability efficacy combination oral daily RAD001 intravenous 3-weekly R1507 patient advance solid tumor . In Part 1 study , patient enrol sequentially receive 5mg mouth ( po ) RAD001 daily + 16mg/kg intravenous ( iv ) R1507 every 3 week ( level 1 ) tolerate , 10mg po RAD001 daily + 16mg/kg iv R1507 every 3 week ( level 2 ) .In Part 2 study , patient 1 ) advance renal cell cancer 2 ) advance pancreatic neuroendocrine tumor receive maximum tolerate dose regimen Part 1 ( 5mg 10mg po RAD001 + 16mg/kg iv R1507 ) . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study mTOR Inhibitor ( RAD001 ) Combination With R1507 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically confirm recurrent refractory advance solid tumor ( Part 1 ) ; advance metastatic renal cell cancer OR advance metastatic pancreatic neuroendocrine tumor , evidence progressive disease ( Part 2 ) ; measurable disease ( Part 2 ) ; ECOG performance status 02. prior treatment agent act via inhibition IGFIR pathway ; prior treatment agent act via inhibition mTOR ( Part 2 ) ; untreated CNS metastasis ; current anticancer therapy , radiotherapy chemotherapy &lt; =4 week prior enrollment ; know malignancy require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>